Accellix

About

Headcount over time

Offices

Q&A

What is Accellix's primary business?

Accellix provides a rapid, easy-to-use, automated cell phenotyping platform for quality control in cell and gene therapy manufacturing and blood characterization.

When was Accellix acquired and by whom?

Accellix was acquired by bioMérieux in January 2026 for approximately $38 million.

What was Accellix's most recent funding round?

Accellix raised a D Round of $10,000,000 in December 2021, with BroadOak Capital Partners as a lead investor.

How many employees does Accellix currently have?

Accellix has 51–200 employees.

What was a significant funding event for Accellix in 2020?

In June 2020, Accellix raised a $9.5 million Series D round with lead investors bioMérieux and existing major investors.

Did Accellix secure any debt financing recently?

In April 2020, Accellix secured $8.5 million in convertible debt financing from existing major investors.

What was a key product development announced by Accellix in 2020?

In April 2020, Accellix announced its next-generation Accellix Instrument and Consumable, designed to further simplify and automate the QC workflow in cell therapy manufacturing.

Team · 9

Harvey Kasdan

Founder · Founder & CTO

Nir Nimrodi

Executive Chairman and CEO

Greg Hamilton

Chief Executive Officer

Félix Montero-Julian

Vice President of Scientific Affairs

Zion Botesazan

Vice President of Hardware and Software

Rey Mali

Vice President Sales and Marketing

Jyothi

Staff Scientist, Assay Migration and Development

Nikhita

Scientific Sales Representative (EMEA)

Shosh

Operations Director

Sectors & technology

Highlights

Tags